Fundamental Analysis of ARMATA PHARMACEUTICALS INC(NYSEARCA:ARMP) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to ARMP. ARMP was compared to 588 industry peers in the Biotechnology industry. ARMP may be in some trouble as it scores bad on both profitability and health. ARMP is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ARMP had negative earnings in the past year.

ARMP had a negative operating cash flow in the past year.

In the past 5 years ARMP always reported negative net income.

In the past 5 years ARMP always reported negative operating cash flow.

1.2 Ratios

ARMP's Return On Assets of -70.20% is on the low side compared to the rest of the industry. ARMP is outperformed by 65.53% of its industry peers.

		Industry Rank	Sector Rank
ROA	-70.2%
ROE	N/A
ROIC	N/A

ROA(3y)-47.31%

ROA(5y)-54.92%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ARMP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ARMP does not have a ROIC to compare to the WACC, probably because it is not profitable.

ARMP has about the same amout of shares outstanding than it did 1 year ago.

ARMP has more shares outstanding than it did 5 years ago.

ARMP has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -5.27, we must say that ARMP is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.27, ARMP is doing worse than 63.65% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-5.27

ROIC/WACCN/A

WACC7.57%

2.3 Liquidity

A Current Ratio of 1.16 indicates that ARMP should not have too much problems paying its short term obligations.

Looking at the Current ratio, with a value of 1.16, ARMP is doing worse than 87.03% of the companies in the same industry.

A Quick Ratio of 1.16 indicates that ARMP should not have too much problems paying its short term obligations.

With a Quick ratio value of 1.16, ARMP is not doing good in the industry: 86.01% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.16
Quick Ratio	1.16

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ARMP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -65.14%.

The Revenue for ARMP has decreased by -17.64% in the past year. This is quite bad

The Revenue has been growing by 76.77% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-65.14%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-89.66%

Revenue 1Y (TTM)-17.64%

Revenue growth 3Y76.77%

Revenue growth 5YN/A

Revenue growth Q2Q45.52%

3.2 Future

Based on estimates for the next years, ARMP will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.34% on average per year.

ARMP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 70.13% yearly.

EPS Next Y24.35%

EPS Next 2Y12.4%

EPS Next 3Y12.15%

EPS Next 5Y14.34%

Revenue Next Year20.14%

Revenue Next 2Y-15.71%

Revenue Next 3Y-25.99%

Revenue Next 5Y70.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ARMP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ARMP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ARMP's earnings are expected to grow with 12.15% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y12.4%

EPS Next 3Y12.15%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ARMP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARMATA PHARMACEUTICALS INC

NYSEARCA:ARMP (5/3/2024, 7:04:00 PM)

2.49

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap90.01M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-70.2%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.05

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.16
Quick Ratio	1.16
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-65.14%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y24.35%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-17.64%

Revenue growth 3Y76.77%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

Scheduled Maintenance

ARMATA PHARMACEUTICALS INC (ARMP)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens